A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with `Systemic Sclerosis associated Interstitial Lung Disease'(SSc-ILD).
Clinical Trial Grant
Administered By
Medicine, Rheumatology and Immunology
Awarded By
Boehringer Ingelheim Pharmaceuticals, Inc.
Start Date
August 15, 2016
End Date
August 14, 2019
Administered By
Medicine, Rheumatology and Immunology
Awarded By
Boehringer Ingelheim Pharmaceuticals, Inc.
Start Date
August 15, 2016
End Date
August 14, 2019